Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction
Details : CBL-514 is a potentially first-in-class small-molecule drug, that can induce adipocytes apoptosis and lipolysis to reduce subcutaneous adiposity. It is being evaluated for fat reduction.
Product Name : CBL-514
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2024
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Caliway Gets Approval for CBL-514 Phase 3 Study on Subcutaneous Fat Reduction
Details : CBL-514, a potential first-in-class small molecule lipolysis injection, is in phase 2 trials for subcutaneous fat reduction by inducing adipocyte apoptosis.
Product Name : CBL-514
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBL-514, a first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis to reduce subcutaneous adiposity in treatment areas in animal studies.
Product Name : CBL-514
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBL-514, a first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis to reduce subcutaneous adiposity in treatment of Moderate to Severe Cellulite.
Product Name : CBL-514
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBL-514, a first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis, being developed in abdominal subcutaneous fat reduction.
Product Name : CBL-514
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBL-514, a first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis to reduce subcutaneous adiposity in treatment areas in animal studies.
Product Name : CBL-514
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : CBL-514
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB825
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Leo Pharma
Deal Size : $570.0 million
Deal Type : Licensing Agreement
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825
Details : Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China.
Product Name : FB825
Product Type : Antibody
Upfront Cash : $40.0 million
April 15, 2020
Lead Product(s) : FB825
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Leo Pharma
Deal Size : $570.0 million
Deal Type : Licensing Agreement